Fidelity SPDR Advertisement
Home > Boards > Canadian > Biotechs >

Vanc Pharmaceuticals Inc. (TSXV:NPH)

TSXV:NPH RSS Feed
Add TSXV:NPH Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator
Search This Board:
Last Post: 11/18/2014 12:29:57 PM - Followers: 23 - Board type: Free - Posts Today: 0
ALDA PHARMACEUTACALS CORP MARKET- TSX VENTURE SYMBOL APH.V SYMBOL- US- APCSF COMPANY WEB SITE: http://www.aldacorp.com/ Name History- ALDA PHARMACEUTACALS CORP- 11/27/03-Present Incorporation Date- 5/30/00- Canada British Columbia Exchange filing Office- Vancouver Regional Filing Office Shares outstanding: 46,379,154 Link to WallStreet.Net Interview by CEO and Director Terrance Owen: 10-26-07 http://www.wallst.net/audio/audio.asp?id=4092 1-31-08 http://www.wallst.net/audio/audio.asp?ticker=TSX.V:APH&id=4441 http://www.cfra.com/chum_audio/Biz@Nite-Terry.Owens.Feb01.08.mp3 Company Overview ALDA Pharmaceuticals Corp. is a public company trading on the TSX Venture Exchange under the symbol APH. The British Columbia based company was founded in 1996 by Dr. Allan Shapiro. ALDA was established to develop and commercialize the T36® technology and market a series of effective infection control products based on this proprietary formulation. Today, the company benefits from an experienced management team with a wide diversity of business experience and a sound knowledge of the pharmaceutical industry. ALDA is focused on the production and marketing of innovative infection control products. The emergence and emergency presented by infectious diseases such as SARS, Norwalk Virus and new strains of influenza has increased the market demand for a highly effective, non-toxic and environmentally friendly disinfectant. ALDA has developed its lead product T36® Distinfectant to combat these virulent pathogens and to serve an ever growing global market that demands high quality infection control products. To date, ALDA has developed a series of infection control products based on its proprietary T36® technology. The current range of products includes: • T36® Distinfectant : A hard-surface disinfectant in a spray formulation. This product was test marketed for three years, before being introduced to the market in 2005 as T36® Distinfectant an infection control solution for "first responders" (ambulances, fire fighters and police), as well as for use in medical and dental offices. ALDA recognizes the universal concerns about infection control and the worldwide market opportunity associated with them. To address this demand, ALDA has obtained regulatory approval in the United Kingdom and secured an Asian distribution agreement for its products in Japan, Taiwan, South Korea, and ASEAN member countries. Major markets for ALDA's products include hospitals, medical clinics, nursing homes, medical and dental offices, laboratories, emergency services departments (including emergency medical services, fire and law enforcement), food manufacturing plants, hotels, restaurants, tattoo parlors, nail & beauty salons, airplanes, and cruise ships. Product Overview ALDA Pharmaceuticals' T36® Disinfectant is the company's flagship product. It is a hard-surface spray disinfectant designed to treat extensive hard surface soiling and to disinfect all washable hard and soft surfaces such as: • Counter tops • Dental and medical chairs • Plastic or acrylic components • Electronic equipment • Tubs (pedicure, podiatric) • Walls and floors • Dental and Surgical instruments • First response vehicles • CPR equipment • Nomex, Kevlar and PBI • Laboratory glassware • Washrooms, showers • Massage and chiropractic tables In: • Critical care use facilities • Hospitals • Medical and dental offices • Healthcare facilities • First aid stations • Nursing homes • Medical research labs • Biohazard spills areas • Animal (& pet) environments • "Scenes of crime" and other areas applicable to the police forces. T36® Disinfectant – Product Highlights • Does not contain bleach, gluteraldehyde, glycols or peroxides • Heat-Induction Foil Seal • Filtered through a 0.20 micron filter • Certified safe and non-irritating • Biodegradable and environmentally friendly • Only virgin packaging materials used • Best available technology for low, medium and high risk exposures • Download the T36® Disinfectant Material Safety Data Sheet (MSDS): English / French Version ------------------------------------------------------ Board Of Directors: • Dr. Terrance G. Owen CEO, President and Director • Peter Chen CFO, Director and Secretary • Dr. Linda Allison Director • Dr. Ronald Zokol Director • Eugene Hodgson Director • Dr. William McCoy Director Audited Financials- June 2006- http://www.aldacorp.com/download/quarterlyreports/063006AUDITED.pdf NEWS RELEASES ------------------------------------------------------- PR'S: VANCOUVER, BRITISH COLUMBIA, Sep 13, 2007 (CCNMatthews via COMTEX) -- ALDA Pharmaceuticals Corp. (the "Company" or "ALDA") (TSX VENTURE:APH) announces that the Company's current auditor, Berris Mangan ("BM"), has resigned as auditor of the Company, effective August 21, 2007, on its own initiative. The Board of Directors has appointed HLB Cinnamon Jang Willoughby Chartered Accountants ("CJW") as the interim auditor of the Company until the annual general meeting. The Company has confirmed that there are no "reportable events" (as such term is defined in National Instrument 51-102 of the Canadian Securities Administrators). BM is now focusing its practice on TSX-listed companies with Canadian reporting responsibilities. ALDA is continuing its work towards registration of its securities and reporting in the US and has appointed CJW so that its financial statements may continue to be prepared and audited in accordance with US requirements. About HLB Cinnamon Jang Willoughby Chartered Accountants CJW is a member firm of HLB International, a world-wide organization of accounting firms and business advisors with 1,750 partners and over 12,000 staff in 440 offices in over 100 countries. HLB member firms, such as CJW, deal with all sizes of clients and types of assignments, ranging from large publicly listed and public sector clients through to owner-managed, director controlled companies. About ALDA Pharmaceuticals Corp. ALDA is focused on the development of infection control therapeutics derived from its patent-pending T36(R) technology. The company trades on the TSX Venture Exchange under the symbol APH. SOURCE: ALDA Pharmaceuticals Corp. CONTACT: ALDA Pharmaceuticals Corp. Terrance G. Owen, Ph.D., MBA President, CEO and Director (604) 521-8300 ALDA Pharmaceuticals Corp. - Distribution & Sales Contact Peter Chen CFO and Director (604) 521-8300 Ext. 3 (604) 521-8322 (FAX) Email: peter_chen@aldacorp.com ALDA Pharmaceuticals Corp. - Investor Relations Contact Scott Young (604) 288-7222 Email: syoung@freeformcom.com Website: www.aldacorp.com ------------------------------------ ALDA Pharmaceuticals Appoints Cowie and Fox to "Rebrand" T36(R) VANCOUVER, BRITISH COLUMBIA, Sep 18, 2007 (CCNMatthews via COMTEX) -- ALDA Pharmaceuticals Corp. ("ALDA") (TSX VENTURE:APH) announces that Cowie and Fox Inc. has been appointed to work with Group 270 Sales & Marketing Inc. to create a new "brand" and marketing program for the Company's T36(R) Personal Disinfectant for the retail market. Dr. Terrance Owen, President & CEO comments, "The T36(R) formulation is a very powerful, safe and versatile infection control agent. We are pleased to have Cowie and Fox working with us to put this unique product into the hands of consumers through the retail chains as quickly as possible". About Cowie and Fox Inc. Cowie and Fox Inc. is a full-service boutique advertising agency in Vancouver, British Columbia. Their team has extensive experience developing, working with, and refreshing, Canadian and international brands such as Please Mum, Vesta Properties, Semperviva Yoga, Bootlegger and lululemon athletica. Their original on- and off-line advertising & branding initiatives have captured the attention of both the national & international press. About Group 270 Sales & Marketing Inc. Group 270 is a full-service sales and marketing agency specializing in bringing innovative non-prescription drugs and personal care products to Canadian consumers through national and regional pharmacy customers, such as London Drugs and Shoppers Drug Mart. About ALDA Pharmaceuticals Corp. ALDA is focused on the development of infection control therapeutics derived from its patent-pending T36(R) technology. The company trades on the TSX Venture Exchange under the symbol APH. ---------------------------------- ALDA Pharmaceuticals Starts Clinical Trials VANCOUVER, BRITISH COLUMBIA, Sep 27, 2007 (CCNMatthews via COMTEX) -- ALDA Pharmaceuticals Corp. ("ALDA" or "the Company") (TSX VENTURE:APH) announces that initial clinical trials of its T36(R) formulation for use as a skin antiseptic, a hygienic hand rub, a pre-surgical hand wash and a pre-injection scrub have been started. On completion, the data from the tests, along with existing and new toxicology information, will be used to support applications in Canada and Europe to test the anti-microbial effectiveness of the formulations with human volunteers. Additional non-human testing will be required before the Company can request human trials in the US. On successful completion of human trials, the Company will be able to pursue the registration and marketing of its products. Dr. Terrance Owen, President & CEO, comments, "This is a significant milestone for the company. We have identified, coordinated and started the testing protocols that are needed for the registration of our products in three major jurisdictions of the world. This simultaneous approach will save time and money and allow us to fast-track sales in Canada and Europe while completing the more extensive testing required by the US." The testing is being conducted by Bioscience Laboratories, Inc. located in Bozeman, Montana. About Bioscience Laboratories, Inc. BioScience Laboratories, Inc. has been providing antimicrobial product testing and result interpretation for various industries, including healthcare, pharmaceutical, personal care and consumer products for over 16 years. ----------------------------- ALDA Pharmaceuticals Retains U.S. Legal Counsel VANCOUVER, BRITISH COLUMBIA, Oct 2, 2007 (Marketwire via COMTEX) -- ALDA Pharmaceuticals Corp. (the "Company" or "ALDA") (TSX VENTURE:APH) announces that Stanislaw Ashbaugh, located in Seattle, Washington, has been retained to assist the Company with U.S. securities law matters. Dr. Terrance Owen, President and CEO states, "In March 2006, the Company completed the filing of its initial 20-F registration statement but we let the matter rest until recently while we contemplated our foreign registration strategies." About Stanislaw Ashbaugh Stanislaw Ashbaugh acts as general corporate counsel to private and public companies engaged in a wide variety of business activities, including middle-sized and emerging growth companies. Of particular interest to ALDA, the broad range of counsel provided by the Corporate/Securities Law Group includes compliance and reporting under federal and state securities laws and secondary financings. ------------------------- ALDA Receives Notice of Allowance for Australian Patent VANCOUVER, BRITISH COLUMBIA, Oct 10, 2007 (Marketwire via COMTEX) -- ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") has been notified that the Australian Patent Office has accepted ALDA's patent application that describes the composition and production methods for ALDA's T36(R) formulation. As in the case of the US and Chinese patent applications which were also recently approved and announced by the company in news releases dated June 26 and June 28, 2007, respectively, the Australian patent application covers the process for making the T36(R) formulation as well as the formulation itself. The components of the T36(R) formulation act synergistically to disrupt the physical structure of the infectious organisms rather than interfering with their metabolic pathways. This provides a high degree of efficacy and safety, prevents microbial resistance and causes no side effects or toxicity to patients. Dr. Terrance Owen, President & CEO, states, "Notification that the patent will now be issued in Australia provides further comfort that our intellectual property is very robust. We are gratified to see rapid allowance of the patent applications in a number of jurisdictions. Clearly, ALDA's T36(R) formulation is unique and is becoming a significant asset to the company." ----------------------------------- AGORACOM Launches "Investor Controlled Discussion Forum" for ALDA Pharmaceuticals Investors in Response to Epidemic Bashing and Spam TORONTO, ONTARIO, Oct 12, 2007 (Marketwire via COMTEX) -- AGORACOM (http://www.agoracom.com) is pleased to announce the launch of an "Investor Controlled Discussion Forum" for investors of ALDA Pharmaceuticals (TSX VENTURE:APH) at http://www.agoracom.com/ir/Alda , as well as, the appointment of "MakingMoneyNow" as HUB Leader. -------------------------------- ALDA Pharmaceuticals to Undertake Private Placement VANCOUVER, BRITISH COLUMBIA, Oct 22, 2007 (Marketwire via COMTEX) -- ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) (the "Company") announces that it is undertaking a private placement of up to 3.5 million units of the Company (the "Units") at a price of $0.15 per Unit for proceeds to the Company of up to $525,000. Each Unit consists of one common share of ALDA and one non-transferable share purchase warrant entitling the holder to acquire one additional common share of ALDA at a price of $0.30 per common share for a period of twelve (12) months from the date of the issuance of the purchase warrant and at a price of $0.45 per common share for the subsequent period of twelve (12) months. The offering is being made on a private placement basis pursuant to registration and prospectus exemptions of applicable securities laws and is subject to acceptance by the TSX Venture Exchange. All securities issued will be subject to a four month restricted period and will bear a restrictive legend accordingly. Net proceeds from the offering will be used for working capital. About ALDA Pharmaceuticals Corp. ALDA Pharmaceuticals Corp. is focused on the development of infection control therapeutics derived from its patent-pending T36(R) technology. The company trades on the TSX Venture Exchange under the symbol APH. SOURCE: ALDA Pharmaceuticals Corp. CONTACT: ALDA Pharmaceuticals Corp. Terrance G. Owen, Ph.D., MBA President, CEO and Director (604) 521-8300 --------------------------------- ALDA Seeks Registration of New Antiseptic Skin Cleanser VANCOUVER, BRITISH COLUMBIA, Oct 30, 2007 (Marketwire via COMTEX) -- ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") has applied to Health Canada for a Drug Identification Number ("DIN") for a new antiseptic skin cleanser. The registration being sought is under a Category IV Monograph which allows Health Canada to provide an automatic registration, usually within 60 days, of infection control products that contain specified levels of anti-microbial ingredients. As announced previously by ALDA, the services of Group 270 and Cowie and Fox have been engaged to create a new name, logo and retail marketing program for ALDA's T36(R) Personal Disinfectant spray. The new antiseptic skin cleanser compliments the T36(R) Personal Disinfectant spray and both products will be marketed under the new name. The new antiseptic skin cleanser is more powerful and provides a higher level of infection control than standard alcohol-based hand rubs. Bundled with the T36(R) Personal Disinfectant spray under the new name, the two products will offer the consumer a versatile package of infection control products for use in the home or while traveling. Dr. Terrance Owen, President & CEO, states, "The antiseptic skin cleaner ties in well with our strategy of introducing effective new products to the consumer market to alleviate concerns about the transmission of infectious diseases. We have completed a search of a new name proposed by Cowie and Fox and will now seek verification that the name can be registered." About ALDA Pharmaceuticals Corp. ALDA is focused on the development of infection control therapeutics derived from its patent-pending T36(R) technology. The company trades on the TSX Venture Exchange under the symbol APH. SOURCE: ALDA Pharmaceuticals Corp. CONTACT: ALDA Pharmaceuticals Corp. ------------------------------------------ ALDA Arranges European Regulatory Assistance VANCOUVER, BRITISH COLUMBIA, Nov 8, 2007 (Marketwire via COMTEX) -- ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") has reached an agreement with Tincali Tech Consulting ("Tincali"), located in the United Kingdom, to assist ALDA with regulatory matters in the EU. The first task undertaken by Tincali is a competitive analysis of the UK market for hand sanitizers. Subsequently, Tincali will define the process required for ALDA to market T36(R) Personal Disinfectant in both the EU and the Middle East using the existing EU registration. This product will be marketed using the new "brand" that is being developed by Cowie and Fox. Tincali will then assist ALDA in coordinating the clinical trials that are required for EU, US and Canadian registration of ALDA's therapeutic products. Dr. Terrance Owen, President & CEO, states, "We are pleased to have Tincali acting on ALDA's behalf in Europe. To accomplish the registration of ALDA's therapeutic products in a timely and efficient manner requires a physical presence in the territory. Now that we have an EU-based consultant, we hope to see significant progress towards marketing ALDA's T36(R) Personal Disinfectant and the new antiseptic hand cleanser in Europe and the Middle East." About Tincali Tech Consulting Tincali is a UK-based consulting group that provides professional services to pharmaceutical companies, including evaluation of potential new products, acquisition of technologies, product commercialization planning, regulatory assessment and market analysis. The Managing Director of Tincali, Dr. Carlos Pittol, has over 12 years of business experience, following completion of a PhD in Chemistry in the UK and a Postdoctoral Research Fellowship in pharmaceutical chemistry at the University of Toronto --------------------- Key developments ALDA Pharmaceuticals Expands Agreement for China 05/31/2007 ALDA Pharmaceuticals Corp. announced that a new, expanded license has been granted for manufacturing, marketing and distribution of ALDA's T36(R) products in China. At ALDA's request, distribution of products manufactured in China to other countries is allowed under this license. Previously, as announced by the company in a news release dated November 30, 2004, a similar license had been granted to Fuzhou Xinmei Biotech Co. Ltd. (Fuzhou) but covered only the province of Fujian. Fuzhou's original license has been transferred to He-Yi She Ye Limited of Fuzhou City (He-Yi). He-Yi is the agent responsible for having arranged testing, registration and manufacturing approval for the T36(R) formulation in China . The new agreement with He-Yi expands the rights previously granted to Fuzhou from the province of Fujian to all of China. He-Yi can now pursue manufacturing, marketing and distribution in all provinces of China in exchange for achieving certain minimum sales levels and the payment of license fees and royalties to ALDA. He-Yi will be promoting the use of ALDA's T36(R) formulation throughout China as a hand sanitizer, first-aid antiseptic and disinfectant. ALDA Pharmaceuticals Corp. Announces Earnings Results for the Third Quarter and Nine Months Ended March 31, 2007 05/30/2007 ALDA Pharmaceuticals Corp. announced earnings results for the third quarter and nine months ended March 31, 2007. For the quarter, the company reported loss of CAD 86,061 or CAD 0.00 loss per share on sales of CAD 72,879 against loss of CAD 118,084 or CAD 0.01 loss per share on sales of CAD 47,694 for the same period a year ago. For the nine months, the company reported loss of CAD 281,509 or CAD 0.01 loss per share on sales of CAD 194,810 against loss of CAD 310,932 or CAD 0.01 loss per share on sales of CAD 164,861 for the same period a year ago. ALDA Pharmaceuticals Corp. Develops Superior Hand Sanitizer 04/19/2007 ALDA Pharmaceuticals Corp. has completed the development of a superior hand sanitizer based on its patent-pending T36(R) infection control technology. Tests indicate that ALDA's T36(R) Hand Sanitizer is approximately 3,000 times more powerful than common alcohol-based hand sanitizers. ALDA has developed this new T36(R) Hand Sanitizer to meet a world-wide demand of $2.5 Billion from consumers, commercial establishments and medical facilities for hand hygiene products. **************************************** ALDA Pharmaceuticals Invited to Ottawa HIV Conference VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 24, 2008) - Representatives of ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") have been invited to attend the 4th Canadian Microbicides Symposium that will take place on January 28, 2008, in Ottawa, Ontario. The event is being organized by the Canadian AIDS Society and is being attended by a select group of approximately 40 invitees from government departments, research organizations, the private sector and community organizations. The goal of the symposium is to implement the Canadian Microbicide Action Plan (CMAP), which is a commitment from Canada to contribute to microbicides both domestically and internationally, with an emphasis on the urgent need for improved products. The AIDS epidemic is in its third decade and it is now very evident that the scale of the AIDS crisis outstrips even the worst case scenarios of a decade ago. Since 1981, 25 million people have died of AIDS worldwide. The CMAP is an important initiative because, globally, it is estimated that 33.2 million people are now infected with HIV/AIDS with 6,800 new cases being reported every day. ALDA's representatives have also been invited to meet with members of the Senate of Canada on Parliament Hill in Ottawa on January 29th, 2008. Participation in this symposium and the subsequent private meetings will provide exposure of ALDA's T36® Microbicide Gel to government and non-government organizations (NGO's), public and private organizations and companies that are striving to prevent the spread of HIV and AIDS. The CMAP was completed in 2006 and includes recommendations on policy and regulatory issues, cross-departmental and cross-sector mechanisms for collaboration, and steps to strengthen commitments to accelerate the development and delivery of microbicides. CMAP is the only plan of its kind in the world. ALDA is privileged to have the opportunity to participate in this multi-sectoral symposium for the purpose of articulating domestic and global contributions from Canada through the CMAP. ******************************** About T36® Microbicide Gel T36® Microbicide Gel is a personal lubricant that is designed to prevent the spread of HIV and other Sexually Transmitted Infections ("STI's"). It contains infection-control ingredients in relatively low concentrations that act synergistically to disrupt the physical structure of microbes rather than interfering with their metabolic pathways. The competitive advantage is its ability to kill STI-causing organisms while preventing microbial resistance, side effects or toxicity. About ALDA Pharmaceuticals Corp. ALDA is focused on the development of infection control therapeutics derived from its patent-pending T36® technology. The company trades on the TSX Venture Exchange under the symbol APH. Terrance G. Owen, Ph.D., MBA, President, CEO and Director ALDA Pharmaceuticals Corp. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release *************************************** ALDA's T36(R) Successfully Completes First Clinical Tests VANCOUVER, BRITISH COLUMBIA, Jan 25, 2008 (Marketwire via COMTEX News Network) -- ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") announces that it has received results from clinical tests of its T36(R) formulation ("T36(R)") for use as a skin antiseptic, a hygienic hand rub, a pre-surgical hand wash and a pre-injection scrub. In these clinical studies, T36(R) demonstrated complete efficacy after only 30 seconds of exposure to all 6 species of bacteria tested, including VRE (Vancomycin-Resistant Enterococcus), MRSA (Methicillin-Resistant Staphylococcus aureus) and MDR (Multi-Drug Resistant) Enterococcus faecium. These three species of bacteria are critical concerns in hospitals, nursing homes and other medical facilities based on their resistance to many antibiotics and other treatments. The clinical testing was completed according to the standards required by the FDA in the US, Health Canada and the European Medicines Agency, which included exposure of the bacteria to T36(R) for periods ranging from 30 seconds to 30 minutes. Dr. Terrance Owen, President & CEO, states, "We were confident that T36(R) would do well in these tests given the extensive studies that ALDA has already done using 3-minute exposure times and the successful 1-minute test against MRSA that we announced on December 6, 2007. However, we needed to conduct new tests to meet the specific requirements of the regulatory agencies in Canada, Europe and the US. We are very pleased that T36(R) performed extremely well in these tests. With this data, we can now start planning human trials for Canada and the EU, as well as preparing for our pre-IND (Investigational New Drug) meeting with the FDA. After that meeting, we will know precisely what further testing is required before starting human trials for submission to the FDA." About Bioscience Laboratories, Inc. BioScience Laboratories, Inc. located in Montana, has been providing antimicrobial product testing and result interpretation for various industries, including healthcare, pharmaceutical, personal care and consumer products for over 16 years. About ALDA Pharmaceuticals Corp. ALDA is focused on the development of infection-control therapeutics derived from its patent-pending T36(R) technology. The company trades on the TSX Venture Exchange under the symbol APH. Yahoo!My Yahoo!Mail Make Y! your home pageYahoo! SearchSearch:Sign In New User? Sign UpFinance Home -Help Home InvestingMarket OverviewMarket StatsStocksMutual FundsETFsBondsOptionsIndustriesCurrencyEducationNews & OpinionMarketsInvesting IdeasExpert AdviceSpecial EditionsCompany FinancesProvidersPersonal FinanceBanking & BudgetingCareer & WorkCollege & EducationFamily & HomeInsuranceLoansReal EstateRetirementTaxesHow-to GuidesGet QuotesFinance Search New! Find Quotes Faster You no longer need to remember symbols. Simply type in a company name or stock symbol for instant results. Press Release Source: ALDA Pharmaceuticals Corp. ALDA's T36(R) Highly Effective Against Yeast Infection Microbe Wednesday January 30, 9:24 am ET VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 30, 2008) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH - News; "ALDA") announces that it has received further clinical testing results from BioScience Laboratories, Inc. for the T36® formulation ("T36®"). Complete efficacy was achieved against Candida albicans by T36® within the shortest time required by the FDA, Health Canada and the European Medicines Agency. C. albicans is a major cause of yeast infections which account for one-third of all vulvovaginal infections ("VVI's"). Bacteria are a second major cause of VVI's and combinations of bacteria and fungi cause most of the remaining cases. The effectiveness that T36® has demonstrated against both fungi and bacteria provides important evidence that ALDA's T36® VVI Treatment will provide an effective means to treat all types of VVI's. ADVERTISEMENT Dr. Terrance Owen, President & CEO, states, "The positive test results that we have received on fungi and bacteria are very gratifying. We know that T36® is very effective, but it is essential that ALDA demonstrate this effectiveness under the rigourous conditions required by the pharmaceutical regulatory agencies in the US, Canada and the EU. This is another significant step forward for ALDA and brings us closer to our goal of developing treatments for a wide range of microbial infections." These developments and others will be discussed in interviews with Dr. Owen on WallSt.net web site on Thursday, January 31 and CFRA Radio in Ottawa for their "Business@Night" program at 6:00 PM, also on January *********************************** ALDA Receives Chinese Patent Wednesday February 6, 1:57 pm ET VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 6, 2008) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH - News; "ALDA") is pleased to announce that Chinese Patent Number ZL02829642.7 has been issued by the State Intellectual Property Office of the People's Republic of China. The patent provides protection for the composition and production methods for ALDA's T36® formulation until August 20, 2022. Dr. Terrance Owen, President & CEO, states, "Receiving the Chinese patent is an important part of our intellectual property protection. There were very few modifications to the original patent application required by the Chinese patent office. This makes us very confident about the uniqueness of the technology and we feel that the patent adds credibility to the manufacturing and marketing rights that have been granted to ALDA's agent in China. We are continuing to work towards establishing a manufacturing facility in China in time for the Olympic Games that are taking place in Beijing this year. We are also excited and pleased by the issuance of the Chinese patent because it shows that we are able to deliver on the goals set out in our business plan." About ALDA Pharmaceuticals Corp. ALDA is focused on the development of infection control therapeutics derived from its patented T36® technology. The company trades on the TSX Venture Exchange under the symbol APH. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release. ------------------------------- Transfer Agent: Pacific Corporate Trust Company COMPANY WEB SITE: http://www.aldacorp.com/ -------------------------------------------------- May 02, 2008 19:35 ETCORRECTION FROM SOURCE: ALDA Grants Incentive Stock Options VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 2, 2008) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) - A correction from source is issued with respect to the release disseminated today at 5:15 pm EST. The total number of options outstanding after this grant was noted incorrectly, and has been corrected to read 4,550,000. The corrected release follows: ALDA Pharmaceuticals Corp. ("ALDA") announces that it has granted incentive stock options to certain directors, senior officers, employees and consultants to purchase an aggregate of 900,000 common shares at an exercise price of $0.80 and a term of three years, expiring on May 2, 2011. The options and shares issuable upon exercise, if any, will be subject to a four-month hold period from the date of grant in accordance with TSX Venture Exchange policy. The grant was pursuant to the Company's Rolling Stock Option Plan, which was re-affirmed by the shareholders of the Company on December 14, 2007 and subsequently accepted by the Exchange. The total number of options outstanding after this grant will be 4,550,000. About ALDA Pharmaceuticals Corp. ALDA is focused on the development of infection-control therapeutics derived from its patented T36® technology. The company trades on the TSX Venture Exchange under the symbol APH. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release. For more information, please contact ALDA Pharmaceuticals Corp. Terrance G. Owen, Ph.D., MBA President, CEO and Director (604) 521-8300 or ALDA Pharmaceuticals Corp. - Distribution & Sales Contact Peter Chen (604) 521-8300 Ext. 3 (604) 521-8322 (FAX) Email: peter_chen@aldacorp.com or ALDA Pharmaceuticals Corp. - Investor Relations Contact Scott Young (604) 288-7222 Email: syoung@freeformcom.com Website: www.aldacorp.com
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TSXV:NPH
Current Price
Volume:
Bid Ask Day's Range
Wiki
PostSubject
#4076   http://www.marketwired.com/press-release/vanc-pharmaceuticals-receives-health-ca woodstock135 11/18/14 12:29:57 PM
#4075   New Web Site: http://www.nuvapharm.com woodstock135 02/12/14 02:29:50 PM
#4074   Alda Pharmaceuticals Corp. changed to Nuva Pharmaceuticals Inc. Renee 07/25/13 05:24:44 PM
#4073   Alda Pharmaceuticals director McCoy resigns woodstock135 12/07/12 02:48:47 PM
#4072   Alda Pharmaceuticals arranges $1-million financing woodstock135 12/07/12 02:48:01 PM
#4071   Alda appoints Beukman, Kennedy directors woodstock135 12/07/12 02:47:15 PM
#4070   Dr. Owen: woodstock135 08/13/12 04:49:27 PM
#4069   Nanotech Systems apppoints Owen as Chief Executive Officer, Grace4 07/26/12 01:17:52 PM
#4068   NR on Stockhouse re: debts Grace4 07/02/12 08:08:42 PM
#4067   So as you should see, sp back Drumstick 06/14/12 06:41:34 PM
#4066   As long as Owen is in control you Drumstick 06/06/12 10:49:59 AM
#4065   Darned if I know ... is there actually Grace4 06/05/12 11:57:49 PM
#4064   Someone dropped $56,000 into Alda in April. Drumstick 06/05/12 08:31:56 PM
#4063   Interesting, but it's not surprising to see Drumstick 05/28/12 11:07:43 AM
#4062   Alda gang and Fortunate Sun Mining Grace4 05/21/12 01:57:15 PM
#4061   Complaining on Boards about the stock or the janetcanada 05/05/12 12:43:13 PM
#4060   Checking me out? For your information that Drumstick 05/05/12 11:44:41 AM
#4059   No I do not understand you Drumstick!!! janetcanada 05/05/12 08:41:12 AM
#4058   You're right, I did'nt loose everything. Drumstick 05/04/12 10:31:47 PM
#4057   Write to the POPE!!!- he is the first BANDIT!!!..... janetcanada 05/03/12 02:11:10 PM
#4056   I was referring to the whole crooked economic Drumstick 05/03/12 01:58:57 PM
#4055   Do not understand why you are so "Resentful" janetcanada 05/03/12 01:55:40 PM
#4054   I'm not interested in any stocks period. Drumstick 05/03/12 01:29:24 PM
#4053   Do not know what make you say this: janetcanada 05/03/12 01:28:11 PM
#4052   I don't involve myself in the scam market Drumstick 05/03/12 11:06:37 AM
#4051   In your words....Alda is so very deceiptful .....but janetcanada 05/03/12 12:02:29 AM
#4050   I love the line where he says rather Drumstick 05/02/12 10:58:33 AM
#4049   This is in answer to my latest correspondence woodstock135 04/18/12 05:00:44 PM
#4048   Let's face it, the whole system is Drumstick 03/25/12 06:29:08 PM
#4047   If in fact there has been unethical behaviour Grace4 03/25/12 05:12:38 PM
#4046   Looks like aph has sunk into the category Drumstick 03/25/12 12:24:16 PM
#4045   Alda Pharmaceuticals reinstated for trading woodstock135 03/12/12 09:01:51 AM
#4044   ALDA PHARMACEUTICALS CORP. ("APH") woodstock135 03/08/12 09:48:13 PM
#4043   Great... so Owen & his little band of Drumstick 01/31/12 01:29:24 PM
#4042   Alda Pharmaceuticals shareholders pass AGM resolutions woodstock135 01/30/12 10:26:53 PM
#4041   Hi guys, which is the best broker in Fara 01/28/12 07:28:33 PM
#4040   Actually the meeting is tomorrow. woodstock135 01/26/12 01:40:04 PM
#4039   Anybody know what happened regarding the share consolidation Drumstick 01/26/12 01:27:58 PM
#4038   Check out PYN. Maybe we can make hoper 01/11/12 01:00:50 PM
#4037   News Release re: MoU for acquisition of market-ready Grace4 01/07/12 06:17:13 PM
#4036   Terence G Owen = dishonest, thief, incompetent, Drumstick 12/30/11 12:08:16 AM
#4035   Owen is a crook. He's blown all Drumstick 12/29/11 10:06:25 PM
#4034   woodstock..............Thanks for the info- Sounds like the company SurfinNj 12/29/11 09:39:49 AM
#4033   This is the answer to my latest correspondence woodstock135 12/28/11 08:01:46 PM
#4032   Same to you, sorry I'm late. Drumstick 12/26/11 06:34:27 PM
#4031   There's a Fan Club... Where do I sign woodstock135 12/23/11 08:03:57 PM
#4030   HAHAHAHA........ Merry XMAS janetcanada 12/23/11 07:08:35 PM
#4029   Thanks, more wonderful news. I guess Drumstick 12/23/11 06:08:41 PM
#4028   Thank you and Merry Christmas to you Surf, woodstock135 12/23/11 05:49:00 PM
#4027   Merry Christmas to all.....including T.O.! Best of SurfinNj 12/23/11 04:49:18 PM
PostSubject